Inhibitor Therapeutics, Inc. (INTI) Net income 2016–2025
Inhibitor Therapeutics, Inc. (INTI) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
-$3.3MFY2025 · since FY2016: -$7.0M → -$3.3M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$3.3M | +1.2% |
| FY2024 | -$3.3M | -10.3% |
| FY2023 | -$3.0M | -125.0% |
| FY2022 | $12.1M | +4153.9% |
| FY2021 | -$298,632 | +71.8% |
| FY2020 | -$1.1M | +61.3% |
| FY2019 | -$2.7M | +39.9% |
| FY2018 | -$4.6M | +10.8% |
| FY2017 | -$5.1M | +27.1% |
| FY2016 | -$7.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More INTI financial trends
INTI RevenueINTI Net marginINTI Gross profitINTI Gross marginINTI Operating incomeINTI Operating marginINTI Operating cash flowINTI Free cash flowINTI Capital expendituresINTI Return on equityINTI Stock buybacksINTI Dividends paidINTI Total assetsINTI Total liabilitiesINTI Shareholders’ equityINTI overview →